Systemic Sclerosis-Associated Interstitial Lung Disease: What We Know and How to Incorporate Guidelines into Clinical Practice

By afschroeder • December 16, 2025

Esposito AJ, Selvan KC, Richardson C, Khanna D, Bemiss BC, Bernstein EJ, Chung JH, Cox CW, Dematte JE, Denton CP, Distler O, Hinchcliff ME, Smith V, Strek ME, Varga J, Hoffmann-Vold AM, Volkmann ER. Systemic Sclerosis-Associated Interstitial Lung Disease: What We Know and How to Incorporate Guidelines into Clinical Practice. Chest. 2025 Dec 13:S0012-3692(25)05842-8. doi: 10.1016/j.chest.2025.11.047. Epub ahead of print. PMID: 41397518.

Tags: guidelines, interstitial lung disease, Publications, Rheumatology, screening, systemic sclerosis, Treatment

Waitlist mortality and post transplant survival amongst non-extracorporeal membrane oxygenation high-urgency heart transplant recipients before and after the 2018 policy change

White JP, Song J, Kim ST, Zappacosta H, Cho PD, McKay S, Girish A, Abramov A, Daniel M, Telesca D, Husain M, Ardehali A. Waitlist[...]

Evaluating the 2023 safety-net kidney policy: Eligibility and outcomes of heart transplant recipients in the United States

Zappacosta H, Daniel M, Tan N, Cho PD, Song J, White JP, Ardehali A. Evaluating the 2023 safety-net kidney policy: Eligibility and outcomes of heart[...]

Results from a Phase II Single Arm Trial Evaluating the Safety and Efficacy of Anhydrous Enol-Oxaloacetate on Improving Cognitive Complaints in Breast Cancer Survivors

Ganz PA, Van Dyk K, Crespi CM, Petersen L, Sedrak MS, Bower JE. Results from a Phase II Single Arm Trial Evaluating the Safety and[...]